Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China
3 de septiembre de 2026 actualizado por: Sanofi
A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China
The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.
Study details include:
- Study duration (including 6-month safety follow-up after the last dose):
- Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months)
- Cohort II (Groups 3 and 4): up to 18 months
- Cohort III (Groups 5 and 6): up to 21 months
- Cohort III (Group 7): approximately 16 months
- Vaccination Visits Period:
- Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91).
Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
- Cohort II (Groups 3 and 4): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). A 1-dose booster is planned for Group 3 only at 18 MoA (within the 18th month from the participant's birth date).
Up to 4 blood samples will be collected. In the primary vaccination period, blood samples are collected before the first primary vaccination (D01) and 30 days post the 2nd dose of primary vaccination (D61 or D121). A blood sample will be collected from all participants at 18 MoA. A post-booster blood sample will be collected from participants in Group 3, 30 days post their booster vaccination.
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods, respectively, for safety follow-up.
For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
- Cohort III - Groups 5 and 6: a 3-dose primary vaccination at V01 (D01), V02 (D31) and V03 (D61), a 1-dose booster at 12 MoA (within the 12th months from the participant's birth date) on V05 or at 18 MoA (within the 18th months from the participant's birth date) on V06.
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D91); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 (for participants receiving the booster at 12 MoA) or V06 (for participants receiving the booster at 18 MoA), and 30 days post booster vaccination (V05 + 30 days or V06 + 30 days).
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods respectively for safety follow-up.
- Cohort III - Group 7: a 3-dose primary vaccination at V01 (D01), V02 (D61) and V03 (D121), a 1-dose booster at V05 at 12 MoA (within the 12th months from the participant's birth date).
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D151); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 and 30 days post booster vaccination (V06).
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods (ie, V04 and V06), respectively, for safety follow-up. A safety visit is planned on the 9th day after the first vaccination for the ESDR participants (the first 30 participants in this group).
Descripción general del estudio
Estado
Reclutamiento
Condiciones
Tipo de estudio
Intervencionista
Inscripción (Estimado)
4568
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Trial Transparency email recommended (Toll free for US & Canada)
- Número de teléfono: option 6 800-633-1610
- Correo electrónico: contact-us@sanofi.com
Ubicaciones de estudio
-
-
-
Jingxi, Porcelana, 533899
- Reclutamiento
- Investigational Site Number : 1561001
-
Liuzhou, Porcelana, 545100
- Reclutamiento
- Investigational Site Number : 1561003
-
Tengzhou Town, Porcelana, 543399
- Reclutamiento
- Investigational Site Number : 1561002
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- For Cohort I: Aged 12 months through 23 months on the day of inclusion. For Cohort II: Aged 6 months through 11 months on the day of inclusion. For Cohort III: Aged 2 months through 5 months on the day of inclusion
- Born at full term of pregnancy (≥37 weeks) or born after a gestation period of 27 through 36 weeks and medically stable as assessed by the investigator
- Informed consent form has been signed and dated by the parent(s) or other LAR (and by an independent witness if required by local regulations).
- Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures.
Exclusion Criteria:
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy; or long-term systemic corticosteroid therapy
- History of meningococcal infection
- History of any neurological disorders
- History of Guillain-Barré syndrome
- History of an Arthus-type hypersensitivity reaction after a previous dose of tetanus toxoid-containing vaccine
- At high risk for meningococcal infection during the study
- Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
- Self-reported thrombocytopenia, contraindicating intramuscular injection
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C [99.5℉]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Receipt of any live vaccines within 14 days preceding the trial vaccination or planned receipt of any live vaccines in 14 days following trial vaccination, and receipt of any inactivated vaccines in 8 days preceding the trial vaccination or planned receipt of any live vaccines in 8 days following trial vaccination
- For Cohort I (12 to 23 MoA): receipt of any other meningococcal vaccine except the meningococcal group A polysaccharide vaccine included in the NIP. The time since last vaccination of meningococcal group A or groups A and C polysaccharide vaccine of 6 months or less should be excluded.
- For Cohorts II (6 to 11 MoA) and III (2 to 5 MoA): a vaccination history of any meningococcal vaccine.
- Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
- Participation at the time of study enrollment (or in the 4 weeks preceding the study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
- In an emergency setting, or being hospitalized
- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohort I: Group 1MenACYW 2-dose schedule
2 doses of MenACYW conjugate vaccine to participants aged 12 through 23 MoA
|
Pharmaceutical form:Liquid solution-Route of administration:IM injection
Otros nombres:
|
|
Comparador activo: Cohort I: Group 2 MenACYW135, CanSino 2-dose schedule
2 doses of MenACYW135, CanSino conjugate vaccine to participants aged 12 through 23 MoA
|
Pharmaceutical form:Lyophilized powder (MenAC conjugate vaccine) and liquid solution (MenYW135 conjugate vaccine)-Route of administration:IM injection
|
|
Experimental: Cohort II: Group 3MenACYW 2-dose primary vaccination + 1-dose booster schedule
2-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 6 through 11 MoA
|
Pharmaceutical form:Liquid solution-Route of administration:IM injection
Otros nombres:
|
|
Comparador activo: Cohort II: Group 4 MenACYW135, CanSino 2-dose schedule
2-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 6 through 11 MoA
|
Pharmaceutical form:Lyophilized powder (MenAC conjugate vaccine) and liquid solution (MenYW135 conjugate vaccine)-Route of administration:IM injection
|
|
Experimental: Cohort III: Group 5 MenACYW 3-dose primary vaccination + 1-dose booster schedule
3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 3 through 5 MoA
|
Pharmaceutical form:Liquid solution-Route of administration:IM injection
Otros nombres:
|
|
Comparador activo: Cohort III: Group 6 MenACYW135, CanSino 3-dose primary vaccination + 1-dose booster schedule
3-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 3 through 5 MoA
|
Pharmaceutical form:Lyophilized powder (MenAC conjugate vaccine) and liquid solution (MenYW135 conjugate vaccine)-Route of administration:IM injection
|
|
Experimental: Cohort III: Group 7 MenACYW 3-dose primary vaccination + 1-dose booster schedule
3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 2 MoA
|
Pharmaceutical form:Liquid solution-Route of administration:IM injection
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participants 12 through 23 MoA (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer <1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8
|
30 days post 2nd vaccination (up to Day 121)
|
|
Participants 12 through 23 MoA (Cohort I): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W measured by rSBA
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine
|
30 days post 2nd vaccination (up to Day 121)
|
|
Participants 6 through 11 MoA (Cohort II): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer <1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8
|
30 days post 2nd vaccination (up to Day 121)
|
|
Participants 6 through 11 MoA (Cohort II): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine
|
30 days post 2nd vaccination (up to Day 121)
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
Periodo de tiempo: Day 91
|
30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer <1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8
|
Day 91
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: Day 91
|
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
|
Day 91
|
|
Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
Periodo de tiempo: Day 151
|
30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer <1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8
|
Day 151
|
|
Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: Day 151
|
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7) or MenACYW135, CanSino conjugate vaccine (Group 6)
|
Day 151
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de participantes con eventos adversos inmediatos (AES)
Periodo de tiempo: En 30 minutos después de la vacunación
|
AE sistémicos no solicitados que ocurren dentro de los 30 minutos posteriores a la vacunación
|
En 30 minutos después de la vacunación
|
|
Presence of solicited injection site reactions
Periodo de tiempo: for 8 days, including the day of each study vaccination.
|
(pre-listed in the participant diary and CRF)
|
for 8 days, including the day of each study vaccination.
|
|
Presence of solicited systemic reactions
Periodo de tiempo: for 8 days, including the day of each study vaccination.
|
(pre-listed in the participant diary and CRF)
|
for 8 days, including the day of each study vaccination.
|
|
Presence of unsolicited AEs
Periodo de tiempo: for 30 days including the day of each study vaccination.
|
for 30 days including the day of each study vaccination.
|
|
|
Presence of SAEs
Periodo de tiempo: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
|
Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
|
|
|
Presence of AEs leading to study discontinuation
Periodo de tiempo: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
|
Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
|
|
|
Participants 12 through 23 MoA (Cohort I) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days post 2nd vaccination (up to Day 121)
|
|
|
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA
Periodo de tiempo: 30 days post 2nd vaccination (up to Day 121)
|
30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine.
|
30 days post 2nd vaccination (up to Day 121)
|
|
Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 18 MoA.
Periodo de tiempo: at 18 MoA (up to Day 394)
|
at 18 MoA (up to Day 394)
|
|
|
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA pre-booster dose at 18 MoA
Periodo de tiempo: at 18 MoA (up to Day 394)
|
at 18 MoA (up to Day 394)
|
|
|
Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against booster meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine given at 18 MoA.
Periodo de tiempo: at 18 MoA (up to Day 424)
|
at 18 MoA (up to Day 424)
|
|
|
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) after one dose of booster vaccination of MenACYW conjugate vaccine
Periodo de tiempo: at 18 MoA (up to Day 424)
|
at 18 MoA (up to Day 424)
|
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA
Periodo de tiempo: D91
|
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.
|
D91
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: at 12 and 18 MoA (up to Day 484)
|
pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
|
at 12 and 18 MoA (up to Day 484)
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: at 12 and 18 MoA (up to Day 484)
|
pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
|
at 12 and 18 MoA (up to Day 484)
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: 30 days after 12 and 18 MoA (up to Day 514)
|
30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
|
30 days after 12 and 18 MoA (up to Day 514)
|
|
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA
Periodo de tiempo: 30 days after 12 and 18 MoA (up to Day 514)
|
30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
|
30 days after 12 and 18 MoA (up to Day 514)
|
|
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7).
Periodo de tiempo: D151
|
D151
|
|
|
Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine
Periodo de tiempo: at 12 MoA (up to Day 333)
|
at 12 MoA (up to Day 333)
|
|
|
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine
Periodo de tiempo: at 12 MoA (up to Day 333)
|
at 12 MoA (up to Day 333)
|
|
|
Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)
Periodo de tiempo: 30 days after 12 MoA (up to Day 363)
|
30 days after 12 MoA (up to Day 363)
|
|
|
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)
Periodo de tiempo: 30 days after 12 MoA (up to Day 363)
|
30 days after 12 MoA (up to Day 363)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
22 de agosto de 2026
Finalización primaria (Estimado)
13 de marzo de 2028
Finalización del estudio (Estimado)
26 de julio de 2029
Fechas de registro del estudio
Enviado por primera vez
13 de julio de 2026
Primero enviado que cumplió con los criterios de control de calidad
13 de julio de 2026
Publicado por primera vez (Actual)
17 de julio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de septiembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
3 de septiembre de 2026
Última verificación
1 de septiembre de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- MEQ00093
- U1111-1316-0126 (Identificador de registro: ICTRP)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .